Last reviewed · How we verify
NCT05548257
Mortality and Related Risk Factors After Hip Arthroplasty
trial in Fracture of Neck of Femur (Hip) in 900 participants. Status unknown.
4 August 2023
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 900 |
| Start date | 20 September 2022 |
| Primary completion | 4 August 2023 |
| Estimated completion | 4 August 2023 |
Conditions studied
- Fracture of Neck of Femur (Hip) — all drugs for Fracture of Neck of Femur (Hip) →
- Femoral Head Necrosis — all drugs for Femoral Head Necrosis →
- Dislocation of Hip Joint — all drugs for Dislocation of Hip Joint →
- Dysplasia of Hip Joint — all drugs for Dysplasia of Hip Joint →
Sponsor
RenJi Hospital
Who can join
18 and older, any sex, with Fracture of Neck of Femur (Hip) or Femoral Head Necrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The patients who underwent hip arthroplasty in our hospital from January 2017 to December 2020 were reviewed. The perioperative data were collected, and then the mortality was calculated and the risk factors were analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05548257
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05548257 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 21 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05548257.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing